MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Milestone Pharmaceuticals Inc. (MIST)

Milestone Pharmaceuticals Inc. (MIST)

|||

Balance Sheets Overview

Current Ratio
812.87%
Quick Ratio
791.58%
Cash Ratio
765.09%
Debt to Asset Ratio
89.97%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Accounts receivable, net
    • Prepaid expenses
    • Others
Liabilities Breakdown
    • Accumulated deficit
    • Common shares, no par value, unl...
    • Royalty financing obligation, lo...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Cash and cash equivalents
169,728
71,317
46,685
42,499
Short-term investments
881
112,899
35,900
918
Accounts receivable, net
2,720
1,605
-
-
License receivable
-
1,546
-
-
Research and development tax credits receivable
515
425
808
1,079
Prepaid expenses
1,035
1,210
2,577
748
Inventory, net
4,722
1,826
-
-
Other receivables
726
1,425
700
924
Total current assets
180,327
192,253
86,670
46,168
Operating lease right-of-use assets
829
981
944
1,090
Property and equipment, net
469
500
136
159
Total assets
181,625
193,734
87,750
47,417
Accounts payable
8,454
10,023
-
-
Accounts payable and accrued liabilities
-
-
10,041
8,768
Accrued liabilities
11,983
9,803
-
-
Operating lease liabilities
670
659
483
515
Deferred revenue
1,034
416
-
-
Other current liabilities
43
43
-
-
Total current liabilities
22,184
20,944
10,524
9,283
Operating lease liabilities, net of current portion
192
366
519
641
Senior secured convertible notes
59,207
58,192
56,206
55,238
Royalty financing obligation, long-term
81,763
78,111
-
-
Other long-term liabilities
61
72
-
-
Total liabilities
163,407
157,685
67,249
65,162
Common shares, no par value, unlimited shares authorized, 124,497,980 shares issued and outstanding as of june 30, 2026, 106,236,344 shares issued and outstanding as of december 31, 2025
384,985
373,702
311,776
288,263
Pre-funded warrants - 16,412,925 issued and outstanding as of june 30, 2026, and 16,412,925 as of december 31, 2025
55,649
55,649
55,649
53,076
Additional paid-in capital
62,867
63,367
66,270
42,188
Accumulated deficit
-485,283
-456,669
-413,194
-401,272
Total shareholders' equity
18,218
36,049
20,501
-17,745
Total liabilities and shareholders' equity
181,625
193,734
87,750
47,417
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$169,728K (299.37%↑ Y/Y)Inventory, net$4,722K Accounts receivable, net$2,720K Prepaid expenses$1,035K (38.37%↑ Y/Y)Short-term investments$881K (-4.03%↓ Y/Y)Other receivables$726K (-21.43%↓ Y/Y)Research and developmenttax credits...$515K (-52.27%↓ Y/Y)Total current assets$180,327K (290.59%↑ Y/Y)Operating leaseright-of-use assets$829K (-23.94%↓ Y/Y)Property and equipment,net$469K (194.97%↑ Y/Y)Total assets$181,625K (283.04%↑ Y/Y)Total liabilities andshareholders' equity$181,625K (283.04%↑ Y/Y)Total liabilities$163,407K (150.77%↑ Y/Y)Total shareholders'equity$18,218K (202.67%↑ Y/Y)Accumulated deficit-$485,283K (-20.94%↓ Y/Y)Royalty financingobligation, long-term$81,763K Senior securedconvertible notes$59,207K (7.19%↑ Y/Y)Total currentliabilities$22,184K (138.97%↑ Y/Y)Operating leaseliabilities, net of current...$192K (-70.05%↓ Y/Y)Other long-termliabilities$61K Common shares, no parvalue, unlimited...$384,985K (33.55%↑ Y/Y)Additional paid-in capital$62,867K (49.02%↑ Y/Y)Pre-funded warrants -16,412,925 issued and...$55,649K (4.85%↑ Y/Y)Accrued liabilities$11,983K Accounts payable$8,454K Deferred revenue$1,034K Operating leaseliabilities$670K (30.10%↑ Y/Y)Other currentliabilities$43K